• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Activated AMPK by metformin protects against fibroblast proliferation during pulmonary fibrosis by suppressing FOXM1
Pharmacol Res. 2021 Aug 24:105844. doi: 10.1016/j.phrs.2021.105844. Online ahead of print.ABSTRACTPulmonary fibrosis (PF) is a progressive and devastating lung disease of unknown etiology, excessive fibroblast proliferation serves as a key event to promote PF. Transcription factor forkhead box M1 (FOXM1) is not only a well-known proto-oncogene, but also an essential driver of cell proliferation. Recently, 5'-AMP-activated protein kinase (AMPK) is reported to reduce the incidence of PF. However, it remains elusive whether have an underlying relationship between AMPK and FOXM1 in fibroblast proliferation-mediated PF. Here, t...
Source: Cell Research - August 27, 2021 Category: Cytology Authors: Xuan Gu Yong-Yue Han Chong-Yang Yang Hui-Min Ji Yue-Jiao Lan Yu-Qian Bi Cheng Zheng Jiao Qu Ming-Han Cheng Jian Gao Source Type: research

Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin
CONCLUSION: Inhibition of AKT can enhance the antitumor effect of metformin and would be a promising strategy to sensitize non-small-cell lung cancer to a combination of metformin with radiation or cisplatin.PMID:34230143 | DOI:10.21873/anticanres.15135
Source: Cell Research - July 7, 2021 Category: Cytology Authors: Se-Kyeong Jang Sung-Eun Hong DA-Hee Lee Ji Yea Kim Ji-Young Kim Jungil Hong In-Chul Park Hyeon-Ok Jin Source Type: research